Evolus (EOLS) Non-Current Deffered Revenue (2017 - 2018)
Evolus (EOLS) posted Non-Current Deffered Revenue of $25000.0 for Q4 2018, down 13.79% on a QoQ basis from $29000.0 in Q3 2018, and down 34.21% year-over-year from $38000.0 in Q4 2017.
Evolus (EOLS) Non-Current Deffered Revenue (2017 - 2018) Analysis & Trends
Evolus' Non-Current Deffered Revenue history runs 2 years deep, the most recent figure standing at $25000.0 for Q4 2018.
- Quarterly Non-Current Deffered Revenue fell 34.21% year-over-year to $25000.0 in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $25000.0 (down 34.21% YoY) and the FY2018 annual result came in at $25000.0, down 34.21% from the prior year.
- Non-Current Deffered Revenue was $25000.0 for Q4 2018 at Evolus, down from $29000.0 in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $38000.0 in Q4 2017 and bottomed at $25000.0 in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Evolus | 390.47 Mn | 340.68 Mn | 48.90 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 25,000.00 |
| Sep 30, 2018 | 29,000.00 |
| Jun 30, 2018 | 32,000.00 |
| Mar 31, 2018 | 35,000.00 |
| Dec 31, 2017 | 38,000.00 |